GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress

GeoVax Labs, Inc. announced that members of its executive medical and scientific team will deliver presentations at the upcoming World Vaccine Congress Europe 2025, highlighting interim safety data and specialized vaccine design approaches for its GEO-CM04S1 COVID-19 vaccine in immunocompromised patients. The conference will be held October 13–16, 2025, at the RAI Amsterdam Convention Centre in the Netherlands.

Mark J. Newman, PhD, GeoVax Chief Scientific Officer, will participate in the Special Populations Workshop during the Pre-Congress Workshops on Monday, October 13. His presentation, titled "Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory," will focus on developing vaccine strategies specifically for vulnerable populations who often respond poorly to conventional vaccines. This workshop brings together international experts to address the challenges of vaccine development and deployment for immunocompromised individuals.

Kelly T. McKee, Jr., MD, MPH, GeoVax Chief Medical Officer, will present a scientific poster titled "Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies." The poster highlighting the safety profile of the GEO-CM04S1 COVID-19 vaccine will be on display in the Poster Zone from October 14–16. This data represents crucial safety information for a population that remains at high risk for severe COVID-19 outcomes despite available vaccines.

David Dodd, GeoVax President & CEO, emphasized the importance of this international gathering, stating, "World Vaccine Congress Europe is one of the most important international gatherings in vaccine research, development and policy. We look forward to highlighting the progress of our multi-antigen GEO-CM04S1 in immunocompromised populations, where the need for more effective vaccine options remains urgent." The World Vaccine Congress Europe convenes global experts across science, clinical development, manufacturing, and public health. More details can be found at https://www.terrapinn.com/conference/world-vaccine-congress-europe.

The significance of these presentations lies in addressing a critical public health gap. Immunocompromised patients, including those with hematologic cancers and recipients of cellular therapies, have shown inadequate responses to current COVID-19 vaccines, leaving them vulnerable to severe illness. GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients for whom current authorized COVID-19 vaccines are insufficient, as well as a booster vaccine in patients with chronic lymphocytic leukemia and a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. For more information about the company's clinical trials and updates, visit https://www.geovax.com.

This development matters because it represents progress toward addressing one of the most challenging aspects of COVID-19 protection—ensuring adequate immunity in populations with compromised immune systems. The implications extend beyond COVID-19, as successful vaccine strategies for immunocompromised individuals could inform approaches for other infectious diseases affecting vulnerable populations. The pharmaceutical industry and global health community are closely watching these developments, as effective vaccines for immunocompromised patients could significantly reduce hospitalizations and deaths in this high-risk group, potentially changing standard care protocols for cancer patients and transplant recipients worldwide.